Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

Inclusion Criteria:

• Participant must be at least 18 years old
• Participant must have been diagnosed with a recurrent brain tumor by magnetic resonance imaging (MRI) scan
• Participant must be willing to practice adequate contraception
• Participant must be able to swallow the enzastaurin tablets whole and receive bevacizumab intravenously
• Participant must agree to use the study drug only as instructed by your study doctor and staff.

Exclusion Criteria:

• Women who are pregnant or breastfeeding
• Participants who have significant heart, liver, kidney, or psychiatric disease
• Participants who have an active infection
• Participants who have any recent bleeding in the brain
• Participants who are taking any anti-coagulation or anti-platelet medication [including aspirin, non-steroidal anti-inflammatories, Cyclooxygenase-2 (COX-2) inhibitors]